Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Free Cash Flow (2018 - 2025)

UroGen Pharma's Free Cash Flow history spans 8 years, with the latest figure at -$38.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 179.18% year-over-year to -$38.3 million; the TTM value through Dec 2025 reached -$162.7 million, down 67.66%, while the annual FY2025 figure was -$162.7 million, 67.66% down from the prior year.
  • Free Cash Flow reached -$38.3 million in Q4 2025 per URGN's latest filing, up from -$42.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$13.1 million in Q4 2023 to a low of -$42.4 million in Q3 2025.
  • Average Free Cash Flow over 5 years is -$25.5 million, with a median of -$23.9 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: surged 40.03% in 2023, then crashed 179.18% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$20.3 million in 2021, then dropped by 7.36% to -$21.8 million in 2022, then soared by 40.03% to -$13.1 million in 2023, then dropped by 5.23% to -$13.7 million in 2024, then plummeted by 179.18% to -$38.3 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Free Cash Flow are -$38.3 million (Q4 2025), -$42.4 million (Q3 2025), and -$40.0 million (Q2 2025).